-
公开(公告)号：US20240041873A1
公开(公告)日：2024-02-08
申请号：US18448122
申请日：2023-08-10
申请人： PHARMA MAR, S.A.
发明人： Carmen Kahatt , José María Fernandez , Salvador Fudio , Arturo Soto , Pilar Lardelli , Cristian Fernandez
IPC分类号： A61K31/4995 , A61P11/00 , A61P35/00 , A61K9/00 , A61K31/4738 , A61K31/4745 , A61K31/573 , A61K38/19 , C07D519/00
CPC分类号： A61K31/4995 , A61P11/00 , A61P35/00 , A61K9/0019 , A61K31/4738 , A61K31/4745 , A61K31/573 , A61K38/193 , C07D519/00 , C07B2200/13
摘要： Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
-
公开(公告)号：US20230027502A1
公开(公告)日：2023-01-26
申请号：US17777982
申请日：2020-05-29
申请人： PHARMA MAR, S.A.
发明人： Pilar Calvo , Carmen Kahatt , José María Fernandez , Maria Tobio , Salvador Fudio , Arturo Soto , Pilar Lardelli , Cristian Fernandez , Maria Del Mar Zarzuelo Alba , María de la Concepción Polanco Noain , Sonia Manzanaro López , Honorio Velasco
IPC分类号： A61K31/4995 , A61K31/573 , A61K9/00 , A61K31/4745 , A61K31/4738 , A61K38/19 , C07D519/00 , A61P35/00 , A61P11/00
摘要： Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
-
公开(公告)号：US20240277705A1
公开(公告)日：2024-08-22
申请号：US18560991
申请日：2022-05-19
申请人： PHARMA MAR S.A.
发明人： Carmen Kahatt , Pilar Lardelli , Cristian Fernandez , Arturo Soto
IPC分类号： A61K31/4985 , A61P35/00
CPC分类号： A61K31/4985 , A61P35/00
摘要： The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, for use in the treatment of cancers. The present invention also relates to a compound of formula I or a pharmaceutically acceptable salt or ester thereof, for use in the treatment of cancer at certain dosage regimens.
-
公开(公告)号：US20230390286A1
公开(公告)日：2023-12-07
申请号：US18448145
申请日：2023-08-10
申请人： PHARMA MAR, S.A.
发明人： Carmen Kahatt , José María Fernandez , Salvador Fudio , Arturo Soto , Pilar Lardelli , Cristian Fernandez
IPC分类号： A61K31/4995 , A61P11/00 , A61P35/00 , A61K9/00 , A61K31/4738 , A61K31/4745 , A61K31/573 , A61K38/19 , C07D519/00
CPC分类号： A61K31/4995 , A61P11/00 , A61P35/00 , A61K9/0019 , A61K31/4738 , A61K31/4745 , A61K31/573 , A61K38/193 , C07D519/00 , C07B2200/13
摘要： Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
-
公开(公告)号：US20240041874A1
公开(公告)日：2024-02-08
申请号：US18448124
申请日：2023-08-10
申请人： PHARMA MAR, S.A.
发明人： Carmen Kahatt , José María Fernandez , Salvador Fudio , Arturo Soto , Pilar Lardelli , Cristian Fernandez
IPC分类号： A61K31/4995 , A61P11/00 , A61P35/00 , A61K9/00 , A61K31/4738 , A61K31/4745 , A61K31/573 , A61K38/19 , C07D519/00
CPC分类号： A61K31/4995 , A61P11/00 , A61P35/00 , A61K9/0019 , A61K31/4738 , A61K31/4745 , A61K31/573 , A61K38/193 , C07D519/00 , C07B2200/13
摘要： Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
-
-
-
-
搜索结果
5 条记录 (耗时 0.014 秒)
